Anavex Life Sciences (AVXL) Shares Up 14.5%
Anavex Life Sciences Corp. (NASDAQ:AVXL) shares shot up 14.5% during mid-day trading on Thursday . The company traded as high as $3.71 and last traded at $3.64. 873,913 shares changed hands during mid-day trading, an increase of 115% from the average session volume of 405,848 shares. The stock had previously closed at $3.18.
A number of brokerages recently issued reports on AVXL. Zacks Investment Research upgraded shares of Anavex Life Sciences from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a research note on Tuesday, September 26th. Maxim Group set a $15.00 price objective on shares of Anavex Life Sciences and gave the stock a “buy” rating in a research report on Thursday, October 12th. ValuEngine downgraded shares of Anavex Life Sciences from a “hold” rating to a “sell” rating in a research report on Thursday, September 28th. Finally, Noble Financial restated a “buy” rating and set a $15.00 price objective on shares of Anavex Life Sciences in a research report on Friday, September 29th.
Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings data on Monday, December 11th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.02). equities analysts forecast that Anavex Life Sciences Corp. will post -0.44 earnings per share for the current fiscal year.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.